Welcome to our dedicated page for Voyager Acquisition SEC filings (Ticker: vach), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to untangle a SPAC’s paperwork? Voyager Acquisition Corp’s filings can jump from a routine 10-Q trust update to a surprise 8-K announcing a business-combination — all before you’ve finished your coffee. Pages of sponsor disclosures, redemption deadlines, and warrant adjustments hide the details investors really need.
Stock Titan’s AI steps in so you don’t spend hours skimming dense exhibits. Our platform delivers real-time alerts on Voyager Acquisition Corp insider trading Form 4 transactions, recaps every 8-K material event, and turns each quarterly earnings report 10-Q filing into a concise, plain-English brief. Want to see how sponsor shares convert? The AI highlights it. Need to monitor trust balance shifts? It’s front and center. We also connect the dots across filings: Form S-4 merger proxies, annual report 10-K simplified, and Voyager Acquisition Corp proxy statement executive compensation details are all cross-referenced for you.
Whether you ask, “understanding Voyager Acquisition Corp SEC documents with AI” or “where can I find Voyager Acquisition Corp Form 4 insider transactions real-time,” this page answers. Browse the complete catalog — 10-K, 10-Q, 8-K, Form 4, Schedule 14A — with AI-powered summaries, keyword search, and download options. Save time, follow potential deal milestones, and see every Voyager Acquisition Corp earnings report filing analysis without wading through legalese.
Voyager Acquisition Corp. (VACH) amended its Business Combination Agreement with Veraxa Biotech AG and the shareholders’ representative. The amendment extends the Agreement End Date to August 7, 2026 and revises termination terms to eliminate the Company’s obligation to pay the SPAC Termination Fee for a termination under Section 10.1(i).
The update preserves the proposed deal while giving the parties more time to complete the transaction. The amendment is filed as Exhibit 2.1 and is incorporated by reference.
Voyager Acquisition Corp. (VACH) amended its Business Combination Agreement with Veraxa Biotech AG. The amendment, signed on October 18, 2025, extends the Agreement End Date to August 7, 2026 and revises termination terms to eliminate the Company’s obligation to pay the SPAC Termination Fee in the specific termination scenario referenced in Section 10.1(i).
The update preserves the proposed combination’s pathway while adjusting timing and fee exposure. The company also reiterated standard forward‑looking statement cautions and noted that PubCo intends to file a Form F‑4 registration statement to solicit shareholder approval for the transaction.
FAQ
What is the current stock price of Voyager Acquisition (vach)?
What is the market cap of Voyager Acquisition (vach)?
